Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer

Preoperative chemoradiation improves survival in esophageal and gastroesophageal junction (GEJ) cancer. We evaluated irinotecan and cisplatin as induction chemotherapy followed by concurrent chemoradiation in esophageal cancer.

[1]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[2]  M. Haider,et al.  Phase 2 trial of preoperative irinotecan plus cisplatin and conformal radiotherapy, followed by surgery for esophageal cancer , 2010, Cancer.

[3]  E. Steyerberg,et al.  Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: Results from a multicenter randomized phase III study. , 2010 .

[4]  J. Ajani,et al.  Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction , 2010, Cancer.

[5]  W. Allum,et al.  Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  G. Ku,et al.  Role of neoadjuvant therapy for esophageal adenocarcinoma. , 2009, Surgical oncology clinics of North America.

[7]  M. Stuschke,et al.  Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  P. Catalano,et al.  Long-term survival outcome of E1201: An Eastern Cooperative Oncology Group (ECOG) randomized phase II trial of neoadjuvant preoperative paclitaxel/cisplatin/radiotherapy (RT) or irinotecan/cisplatin/RT in endoscopy with ultrasound (EUS) staged esophageal adenocarcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Wolfgang A Weber,et al.  PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. , 2007, The Lancet. Oncology.

[10]  Val Gebski,et al.  Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. , 2007, The Lancet. Oncology.

[11]  M. Schwaiger,et al.  Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  C. V. D. van de Velde,et al.  Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. , 2006, The New England journal of medicine.

[13]  Farin Kamangar,et al.  Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Orringer,et al.  Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma , 2003, Cancer.

[15]  V. Rusch,et al.  Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Hainsworth,et al.  Preoperative Therapy with Concurrent Paclitaxel/Carboplatin/Infusional 5‐FU and Radiation Therapy in Locoregional Esophageal Cancer: Final Results of a Minnie Pearl Cancer Research Network Phase II Trial , 2003, Cancer journal.

[17]  S. Larson,et al.  Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  V. Rusch,et al.  A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: initial results. , 2002, The Journal of thoracic and cardiovascular surgery.

[19]  M. Schwaiger,et al.  Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  H. Safran,et al.  Paclitaxel, Cisplatin, and Concurrent Radiation for Esophageal Cancer , 2001, Cancer investigation.

[21]  J. Ciezki,et al.  Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Talamini,et al.  Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  N. Vakil,et al.  A controlled trial of an expansile metal stent for palliation of esophageal obstruction due to inoperable cancer. , 1993, The New England journal of medicine.

[24]  J. Cooper,et al.  Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. , 1992, The New England journal of medicine.

[25]  V. Gebski,et al.  AUSTRALASIAN GASTRO-INTESTINAL TRIALS GROUP. SURVIVAL BENEFI TS FROM NEOADJUVANT CHEMORADIOTHERAPY OR CHEMOTHERAPY IN OESOPHAGEAL CARCINOMA: A META-ANALYSIS , 2007 .

[26]  M. Bains,et al.  Phase I trial of combined-modality therapy for localized esophageal cancer: escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  D. Neuberg,et al.  Neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus: a preliminary analysis of the phase II intergroup trial 0122. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.